Anuh Pharma Limited has published its unaudited financial results for the quarter ended December 31, 2025, in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The pharmaceutical company announced the publication through advertisements in Financial Express (English) and Mumbai Lakshdeep (Marathi) editions on February 8, 2026.

Financial Performance Highlights

The company demonstrated strong financial performance during the third quarter of FY26. Total revenue from operations reached ₹19,717.81 lakhs, marking substantial growth from ₹15,051.33 lakhs in the corresponding quarter of the previous year. This represents a significant improvement in the company's operational scale and market reach.

| Financial Metric: | Q3 FY26 | Q3 FY25 | Growth || | ---: | :--- | :--- | :--- | | Total Revenue from Operations: | ₹19,717.81 lakhs | ₹15,051.33 lakhs | Strong growth | | Net Profit Before Tax: | ₹1,782.82 lakhs | ₹1,326.55 lakhs | Improved | | Net Profit After Tax: | ₹1,345.10 lakhs | ₹1,034.31 lakhs | Enhanced | | Basic EPS: | ₹1.34 | ₹1.03 | Higher |

Nine Months Performance

For the nine months ended December 31, 2025, Anuh Pharma achieved total revenue from operations of ₹56,954.02 lakhs compared to ₹46,337.54 lakhs in the corresponding period of the previous year. Net profit after tax for the nine-month period stood at ₹2,938.47 lakhs, while the previous year recorded ₹3,489.49 lakhs.

Profitability and Margin Analysis

The company maintained healthy profitability metrics during the quarter. EBITDA for Q3 FY26 was ₹2,091.04 lakhs with an EBITDA margin of 10.60%. The adjusted EBITDA, which accounts for forex gains/losses and mark-to-market on mutual fund investments, reached ₹2,402.53 lakhs, representing an adjusted EBITDA margin of 12.18%.

Share Capital and Earnings

The company's paid-up equity share capital stood at ₹5,011.20 lakhs with a face value of ₹5 per share. Basic and diluted earnings per share for Q3 FY26 were ₹1.34, compared to ₹1.03 in the corresponding quarter of the previous year. For the nine months ended December 31, 2025, basic and diluted EPS were ₹2.93.

Regulatory Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. The publication includes a Quick Response Code and webpage details where complete financial results are accessible, ensuring transparency and compliance with regulatory requirements. The results are simultaneously available on the company's website at www.anuhpharma.com .

Anuh pharma Limited has received an Income Tax Assessment Order from the Income Tax Department for Assessment Year 2020-21, resulting in a tax demand of ₹78,28,793. The pharmaceutical company disclosed this development to stock exchanges on January 21, 2026, in compliance with SEBI listing regulations.

Assessment Order Details

The Income Tax Department's Assessment Unit issued the order under Section 143(3) read with sections 263 and 144B of the Income Tax Act, 1961. This was followed by a Tax Demand Order under Section 156 of the same Act. The assessment pertains to the scrutiny assessment for Assessment Year 2020-21, covering the financial year 2019-20.

Nature of Tax Demand

The tax demand arose due to disallowances of certain deductions claimed by the company under various provisions of the Income Tax Act. The total amount of ₹78,28,793 includes applicable interest on the disallowed deductions. The company completed the regular assessment process, which resulted in these disallowances being contested by the tax authorities.

Company's Response and Impact Assessment

Anuh Pharma Limited has indicated its intention to challenge the assessment order through proper legal channels. The company plans to file an appeal before Higher Appellate Forums within the prescribed timelines. Management believes it possesses adequate factual and legal grounds to reasonably substantiate its position in the matter.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided details as required under Para A (20) of Part A of Schedule III to the SEBI LODR regulations. The disclosure has also been uploaded on the company's website at www.anuhpharma.com for public access.

The company's shares trade on BSE under scrip code 506260 and on NSE under the symbol ANUHPR in the EQ series. This regulatory filing ensures transparency with stakeholders regarding material developments that could potentially affect the company's operations or financial position.